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Inhaled nitric oxide (NO) is occasionally used to treat hypoxemia for patients with acute respiratory distress 
syndrome (ARDS) in the intensive care unit (ICU).  However, it is controversial whether or not to maintain 
inhalation of NO during general anesthesia because of complications, such as nitrogen dioxide (NO2) production, 
methemoglobinemia, and inhibition of platelet aggregation.  In this case, a 67-year-old male fell from a roof and 
was brought to an emergency care center. During management, he vomited gastric contents and aspirated.  In spite 
of tracheal intubation and mechanical ventilation with high oxygen therapy, the hypoxia did not improve.  NO 
inhalation with mechanical ventilation was performed to treat hypoxemia due to ARDS in the ICU.  We maintained 
the NO inhalation during the surgery for a hemoperitonium.  The surgery was completed without intra-operative 
hemodynamic instability or any complications.  (Korean J Anesthesiol 2010; 58: 485-489)
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    One of the toxic pollutants, NO, is known as a free radical 
gas. In recent years, however, NO is an endothelial-derived 
vasodilator molecule and has been examined as a supplemental 
treatment agent for pulmonary hypertension. It has also been 
reported that the peri-operative portopulmory hypertension 
which occurs during liver transplantation is controlled by 
the administration of NO and prostacyclin [1,2]. In patients 
with ARDS, ongoing studies are determining whether or not 
oxygenation can be enhanced by the pulmonary vasodilation 
as a supplemental treatment agent [3]. Because the side effects 
due to NO2 occurring during the persistent use of NO cannot 
be overlooked, that the safety of continued use of NO during 
general anesthesia when used pre-operatively needs to be 
determined.
    We managed a case of ARDS due to pulmonary aspiration in 
which NO which was used in the ICU to improve oxygenation 
and was maintained during abdominal surgery. Herein we 
report our case with a review of the literature.486 www.ekja.org
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Case Report
    A 67-year-old man weighing 80 kg had no other notable 
findings than a history of diabetes mellitus, and the patient 
visited the emergency care center with a chief complaint of 
hemoperitonium occurring after a fall injury from a 3 m height. 
At the time of admission, the patient had a clear mentality 
and spontaneous respirations. Due to persistent intra-
abdominal bleeding, the patient had the following findings: 
blood pressure (BP), 85/50 mmHg; and heart rate (HR), 110 
beats/min. During treatment at the emergency care center, 
the patient aspirated gastric contents, which led to tracheal 
intubation. Despite the infusion of dopamine (20 μg/kg/min), 
the patient remained hypotensive. To stop the abdominal 
bleeding, emergency surgery was performed. Sedation was 
continued post-operatively, and the patient was transferred to 
the ICU intubated. On postoperative day 1, during treatment 
with sedation and ventilator care in the ICU, hemodialysis was 
performed due to the occurrence of sepsis and acute renal 
failure (ARF). This was followed by the occurrence of ARDS 
due to pulmonary aspiration (Fig. 1). Controlled mechanical 
ventilation (CMV) was initiated with the following settings: 
tidal volume (TV), 480 ml; respiratory rate (RR), 20 breaths/
min; FiO2, 1.0; and positive end expiratory pressure (PEEP), 15 
mmHg. An arterial blood gas analysis (ABGA) was performed 
which showed the following: pH, 7.01; PaCO2, 60 mmHg; PaO2, 
47 mmHg; HCO3
-, 15.1 mmol/L; and SaO2, 58%. To improve 
oxygenation, NO was administered at a dose of NO from 3:00 
pm on post-operative day 1 (Table 1).
    Until post-operative day 2 following the use of NO, an ABGA 
was performed under the following CMV settings: TV, 450 
ml; RR, 22 breaths/min; FiO2, 1.0; and PEEP, 20 mmHg. The 
Table 1. Changes of Ventilator Mode and Arterial Blood Gas Analysis (ABGA) Data
Before NO After NO Intra-op Post-op POD 1
Ventilator mode
    Tidal volume (ml)
    Frequency (rate/min)
    FiO2 (%)
    PEEP (mmHg)
ABGA
    pH
    PaCO2 (mmHg)
    PaO2 (mmHg)
    O2Sat (%)
    HCO3
- (mmol/L)
480
  20
100
  15
7.01
  60
  47
  58
15.1
450
  22
100
  20
7.27
  46
126
98.4
20.7
550
  16
  80
  10
7.18
  45
430
100
16.8
550
  16
  80
  10
7.20
  39
305
100
15.2
500
  20
100
  20
7.29
  42
  71
  92
20.2
Before NO: before using Inhaled NO, After NO: after using inhaled NO, Intra-op: during operation with inhaled NO, Post-op: immediately post-
operative ABGA with inhaled NO, POD 1: one day after operation without NO.
Fig. 1. Chest AP before using nitric oxide (NO) treatment shows 
increased perihillar opacity, pulmonary edema in lung fields.
Fig. 2. Chest AP after using nitric oxide treatment shows more 
resolved pulmonary edema, but still remained prominent vascular 
marking and consolidation on the right lower lobe.487 www.ekja.org
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ABGA showed as the following: pH, 7.27; PaCO2, 46.1 mmHg; 
PaO2, 126.7 mmHg; HCO3
-, 20.7 mmol/L; and SaO2, 98.4%. 
Thus, oxygenation was gradually improving (Table 1). Due to 
the persistent presence of abdominal bleeding, an emergency 
repeat surgery was performed. While maintaining NO inha-
lation, the patient was transferred to the operating room (Fig. 2).
    Upon arrival in the operating room, the patient had the 
following implants: a catheter in the right subclavian vein for 
central venous pressure (CVP) monitoring, a catheter in the 
right femoral vein for fluid supply, a catheter in the right radial 
artery for a continuous arterial blood pressure monitoring, and 
a colostomy. To maintain vital signs, the patient received an 
infusion of vasopressin (1 unit/hr), dopamine (15 μg/kg/min), 
norepinephrine (0.8 μg/kg/min), and bicarbonate (20 mEq/
hr). The patient also had a BP of 103/55 mmHg, a HR of 110 
beats/min, and a CVP of 21 mmHg. Mechanical ventilation was 
performed using a ventilator (Savina, Drager, Germany) which 
was used in the ICU. With continued CMV (TV, 400 ml; RR, 22 
breaths/min; FiO2, 1.0; and PEEP, 18 mmHg), the measurements 
were as follows SaO2, 85-90%; and a peak inspiratory pressure 
(PIP), 34 mmHg. NO was infused to the area which was 30 cm 
remote from the Y-piece of the inspiratory limb of the ventilator 
using a NO delivery system (HY-1002; Metran Co., Germany). 
In the connecting part between the Y-piece and inspiratory 
limb, using an expiratory gas analyzer (PrinterNOx; Micro 
Medical Ltd., England), the concentrations of NO and NO2 were 
measured (Fig. 3 and 4).
    The patient’s mental status was sedated with midazolam, 
which was used in the ICU (the bispectral index [BIS] was 8). 
Because the ventilator which was used in the ICU was also 
used in the operating room, due to a lack of availability of a 
vaporizer, the induction and maintenance of anesthesia were 
performed using total intravenous anesthesia. With reference 
to BIS measurements, a small dose of propofol (2.0 μg/ml) and 
remifentanil (2.0 ng/ml) were administered using a target-
controlled infusion (Orchestra
TM; Fresenius Vial, France). A 
muscle relaxant, atracurium, was intravenously adminsitered 
at a dose of 20 mg/hr. Intra-operatively, BIS was abruptly 
increased from approximately 10 to 35. Because the BP was 
not sufficiently higher for the enhancement of the propofol 
infusion, to maintain the depth of anesthesia, midazolam was 
intravenously injected twice at a dose of 1 mg. Intra-operatively, 
the concentration of NO was maintained at 5.0-9.5 ppm, and 
NO2 was 0-0.8 ppm. With aggravation of the patient’s vital 
signs, a Swan-Ganz catheter for pulmonary artery pressure 
(PAP) monitoring was not placed. Following the initiation of 
surgery, abdominal decompression was performed. Meanwhile, 
the BP decreased from 120/50 mmHg to 95/40 mmHg. The CVP 
decreased from 21 mmHg to 15 mmHg. The SaO2 increased 
from 90% to 100%. The PIP decreased from 34 mmHg to 24 
mmHg. Blood was used as fluid therapy and an intravenous 
infusion of phenylephrine resulted in an elevation of BP to 
approximately 110/50 mmHg. Thereafter, during the surgery, 
there were no notable changes in the patient’s status. At the 
time the surgical procedure was completed, with a continuous 
infusion of vasopressin (1 unit/hr), dopamine (15 μg/kg/min), 
norepinephrine (0.8 μg/kg/min) and bicarbonate (20 mEq/
hr), the BP was 123/56 mmHg, the HR was 78 beats/min, and 
the CVP was 13 mmHg. Mechanical ventilation was finally set 
at a TV of 500 ml, a RR of 16 breaths/min, a FiO2 of 0.8 (O2, 3.2 
L/min; and N2O, 0.8 L/min), and a PEEP of 10 mmHg in an 
effort to not further increase the PIP, TV, and minute volume. 
Fig. 3. The photograph shows a NO gas dosage machine (PrinterNOx, 
Micro Medical Ltd., England), NO gas supplying line (white arrow) 
and monitoring line (black arrow).
Fig. 4. The photograph shows a NO gas supplying line (white arrow) 
that is con  nected as 30 cm from the Y-piece on the inspiratory limb 
and the moni  toring line (black arrow) is placed at the inspiratory 
limb just behind the Y-piece.488 www.ekja.org
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With the maintenance of the concentration of NO at 5.0-10 
ppm, an ABGA was performed, and showed the following: pH, 
7.18; PaCO2, 45 mmHg; PaO2, 430 mmHg; HCO3
-, 16.8 mmol/
L; SaO2, 100%; and PIP, 25 mmHg (Table 1). At this time, the 
BIS was 13-20. The intra-operative blood loss was 1,000 ml. 
With the transfusion of PRC (4 units), FFP (6 units), and PC (10 
units), the Hb was maintained at 9.2 mg/dl. The anesthetic and 
surgical time was 2 hours and 50 minutes and 2 hours and 20 
minutes, respectively.
    Following surgery, the patient was transferred to the ICU. 
The CMV settings were as follows: TV, 550 ml; RR, 16 breaths/
min; FiO2, 0.8; and PEEP, 10 mmHg. An ABGA analysis showed 
as the following: pH, 7.20; PaCO2, 39 mmHg; PaO2, 305 mmHg; 
HCO3
-, 15.2 mmol/L; and SaO2, 100% (Table 1). The patient’s 
status was considered to be improved. The use of NO was 
therefore discontinued (Fig. 5). Following the repeat surgery, 
however, the abdominal bleeding persisted. There were no 
further improvements in ARDS. On post-operative day 1, at 
approximately 5:00 pm, with the following CMV settings: TV, 
500 ml; RR, 20 breaths/min; FiO2, 1.0; and PEEP, 20 mmHg, 
an ABGA was obtained (pH, 7.29; PaCO2, 42 mmHg; PaO2, 71 
mmHg; HCO3
-, 20.2 mmol/L; and SaO2, 92%; Table 1). Due 
to a lack of response to an increased dose of epinephrine and 
norepinephrine, systolic blood pressure was not maintained at 
>80 mmHg. At dawn on post-operative day 2, due to multiple 
organ failure, including ARF, sepsis, aspiration pneumonia, and 
respiratory failure, the patient expired.
Discussion
    In patients who concurrently have hypoxic pulmonary vaso-
constriction (HPV) and pulmonary hypertension due to alveolar 
hypoxia, such as ARDS, NO has been used as a supplemental 
treatment agent when hypoxemia is not resolved with oxygen 
supply and the appropriate mechanical ventilation. The current 
patient developed ARDS due to pulmonary aspiration. Due to 
persistent intra-abdominal bleeding, the abdominal pressure 
was elevated, and the patient had decreased pulmonary function. 
The most severe form of acute lung injury (ALI), ARDS, has 
been reported to have various causes. It can be defined as cases 
in which the PaO2/FiO2 is <200 mmHg (ALI PaO2/FiO2 <300 
mmHg) and a pulmonary-capillary wedge pressure is <18 
mmHg, despite the presence of bilateral pulmonary infiltrates 
on chest radiography [4]. According to ARDS NET reports [5], 
to reduce pulmonary injury due to mechanical ventilation and 
to assure that the PIP and plateau pressure does not exceed 30 
cmH2O, a low TV (4-8 ml/kg), and a respiratory rate which 
is appropriate for each age group, has been recommended. 
The same methods are also applied to mechanical ventilation 
during anesthesia. In cases in which sufficient oxygenation 
cannot be achieved by these methods, although PEEP which 
is used as a supplemental method should prevent the alveolar 
atelectasis and reduce an intrapulmonary shunting, the effects 
of NO in reducing the intrapulmonary shunt due to pulmonary 
reperfusion from the affected sites to normal alveoli has been 
improved. Besides, there are also effects of NO in lowering 
the pulmonary hypertension [6,7]. But it cannot enhance the 
survival of patients. Also, due to side effects occurring following 
a long-term use of NO, it is not generally used for cases of ALI or 
ARDS. In patients who have severe hypoxia or life-threatening 
pulmonary hypertension, it is used as a supplemental treatment 
agent during a short-term period [7].
    The patient reported herein had severe ARDS because of the 
elevation of abdominal pressure due to the persistent intra-
abdominal bleeding, even after surgery, as well as pulmonary 
aspiration occurring at the emergency care center at the time 
of admission. With a single use of positive pressure ventilation, 
the hypoxia was not improved in the ICU. As a supplemental 
treatment agent, NO was used at a dose of 5.0-9.5 ppm. As 
a result, the ABGA findings were improved from a PaO2 of 47 
mmHg and an oxygen saturation 58% prior to the use of NO 
at a FiO2 of 1.0 to a PaO2 of 126.7 mmHg and a SaO2 of 98.4% 
following the use of NO.
    NO has been used to improve pulmonary oxygenation. But 
the long-term use of NO may cause several complications, 
and these include the synthesis of methemoglobin, the 
synthesis of nitrogen oxide, and an inhibitory effect on platelet 
aggregation. In the current case, however, the reasons that NO 
was maintained during surgery are that discontinuation of NO 
would aggravate the pulmonary hypertension, increase the 
pulmonary vascular resistance, decrease the cardiac output, 
Fig. 5. Immediate postoperative chest AP using inhaled NO shows 
stationary state.489 www.ekja.org
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decrease the mixed venous oxygen saturation (SvO2), decrease 
the systemic arteral blood pressure, and decrease the PaO2. 
Christenson et al. [8] conducted a study in 31 patients with 
acute hypoxemic respiratory failure (AHRF) who inhaled NO. 
According to this study, following the discontinuation of NO 
treatment, such parameters as PaO2, SvO2, and PAO2/FiO2 were 
significantly decreased. Kim et al. [9] reported that rebound 
pulmonary hypertension developed frequently in cases in 
which the use of NO was abruptly discontinued at a lower dose 
after its concentration was lowered during a short-term period. 
Rebound pulmonary hypertension occurs due to various causes 
and obscure mechanisms. These authors therefore proposed 
that a gradual discontinuation be done through repeated 
attempts during a long-term period with special attention paid 
to hemodynamic stability.
    In regard to the optimal NO concentration, there are various 
reports [7,10-12]. Continual use of NO (10 ppm) caused a 
left shift of the dose-response curve and this leads to an 
improvement of arterial oxygenation and mean PAP. But a 
maximal dose of NO (100 ppm) may aggravate oxygenation 
[7]. In association with this, Adhikari et al. [13] conducted 
a systematic review and a meta-analysis and these authors 
reported that methemoglobinemia and ARF would occur 
in cases in which a high dose of NO (>80 ppm) was used for 
several days. 
    Nishimura et al. [10] maintained that NO2 was not generated 
in cases in which NO would be used at a dose <20 ppm. Accor-
ding to another study, in cases in which NO was used at a 
dose of 20 ppm at FiO2 0.9, NO2 was generated at a dose of < 
approximately 0.4 ppm [12]. Based on these reports, in cases 
in which the concentration of NO was maintained as <20 
ppm during anesthesia, the concentration of NO2 would not 
exceed 5 ppm as a safety limit of NO2 [14]. Accordingly in the 
current case, a low dose of NO (5.0-9.5 ppm) was used during 
anesthesia.
    In the current case, NO was used since one day prior to surgery. 
Therefore, the period of use was not relatively longer and a low 
dose of NO was used. Complications due to the use of NO did 
not occur prior to and following the surgery. The surgery went 
well without specific problems. It is regrettable, however, that 
changes in the PAP pre-operatively and post-operatively could 
not be measured due to a lack of the preoperative preparation 
of a Swan-Ganz catheter for a PAP monitoring.
    If the occurrence of NO2 is minimized, the problems occurring 
following a sudden discontinuation of NO use pre-operatively 
rather than complications occurring because of the use of NO 
would be more problematic. In conclusion, the maintenance 
of NO inhalation during anesthesia, rather than a sudden 
discontinuation of NO use pre-operatively, would be beneficial 
for the hemodynamic stability of patients.
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